the staff of the Ridgewood blog
Ridgewood NJ, Pharmaceutical company Novo Nordisk’s weight-loss drug Wegovy was found to significantly reduce the risk of major heart issues, according to a study released yesterday. Analysts suggest the results could help decrease the cost of the new class of semaglutide-based weight-loss drugs—including Ozempic—often labeled as nonmedical treatments by insurers.